Dudediligence.

Lexaria Bioscience Corp

LEXXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$84,000Aug ’24$183,923Nov ’24$174,000Feb ’25$174,000May ’25$174,000Aug ’25$0.00Nov ’25$20,000Feb ’26$0.00May ’26
Net income, by quarter
−$2.2MAug ’24−$2.7MNov ’24−$2.7MFeb ’25−$3.8MMay ’25−$2.7MAug ’25−$1.6MNov ’25−$1.4MFeb ’26−$2.0MMay ’26
Fiscal years, by the month each ended
LineAug 2021Aug 2022Aug 2023Aug 2024Aug 2025
Revenue$722,738$255,397$226,208$464,278$705,923
Gross profit$547,392$183,556none on file$459,456$703,203
Operating income−$5.7M−$6.6M−$6.5M−$5.8M−$11.9M
Net income−$4.0M−$7.3M−$6.7M−$5.8M−$11.9M
Operating cash flow−$4.0M−$4.9M−$5.9M−$5.0M−$10.5M
Free cash flownone on file−$4.9M−$5.9M−$5.0M−$10.5M
Cash$10.9M$5.8M$1.4M$6.5M$1.8M
Shares outstanding5.7M6.0M8.1M15.8M19.6M